| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
2-Pyrrolidinone, 1-(phenylmethyl)-4-(9H-purin-6-ylamino)-, (4S)- manufacturers
- Benpyrine
-
- $2500.00
-
2026-07-27
- CAS:2550398-89-3
- Purity:
- Supply Ability: 10g
|
| | 2-Pyrrolidinone, 1-(phenylmethyl)-4-(9H-purin-6-ylamino)-, (4S)- Basic information |
| | 2-Pyrrolidinone, 1-(phenylmethyl)-4-(9H-purin-6-ylamino)-, (4S)- Chemical Properties |
| Boiling point | 699.1±55.0 °C(Predicted) | | density | 1.456±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | pka | 10.01±0.10(Predicted) | | form | Solid | | color | White to yellow |
| | 2-Pyrrolidinone, 1-(phenylmethyl)-4-(9H-purin-6-ylamino)-, (4S)- Usage And Synthesis |
| Uses | Benpyrine is a highly specific and orally active TNF-α inhibitor with a KD value of 82.1 μM. Benpyrine tightly binds to TNF-α and blocks its interaction with TNFR1, with an IC50 value of 0.109 μM. Benpyrine has the potential for TNF-α mediated inflammatory and autoimmune disease research[1]. | | in vivo | Benpyrine (25-50 mg/kg; oral gavage; daily; for 2 weeks; Balb/c mice) treatment significantly relieves the symptoms of collagen-induced arthritis. Benpyrine dose-dependently decreases the levels of proinflammatory cytokines, such as IFN-γ, IL-1β and IL-6, and increases the concentration of the anti-inflammatory cytokine IL-10[1].
Endotoxemia murine model shows that Benpyrine (25 mg/kg) could attenuate TNF-α-induced inflammation, thereby reducing liver and lung injury[1]. | Animal Model: | Balb/c mice (18-20 g) injected with collagen[1] | | Dosage: | 25 mg/kg, 50 mg/kg | | Administration: | Oral gavage; daily; for 2 weeks | | Result: | Relieved the symptoms of collagen-induced arthritis in mice.
|
| | References | [1] Weiguang Sun, et al. Discovery of an Orally Active Small Molecule TNF-α Inhibitor. J Med Chem. 2020 Jul 15. DOI:10.1021/acs.jmedchem.0c00377 |
| | 2-Pyrrolidinone, 1-(phenylmethyl)-4-(9H-purin-6-ylamino)-, (4S)- Preparation Products And Raw materials |
|